AMEX
0.25USD
-0.00 (-1.26%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
856K
P/E
—
EPS
—
Beta
1.19
52W range
0.21-2.8904
Day range
0.25–0.25
Open
0.25
Prev close
0.25
Volume
272.3K
Avg volume
28M
Dividend
0.00
IPO
1995-11-02
https://www.globenewswire.com/news-release/2026/08/12/3343661/29489/en/aim-immunotech-ceo-highlights-biodefense-and-military-force-protection-in-newly-published-breaking-defense-article.html · 8/12/2026+0.40
https://www.globenewswire.com/news-release/2026/06/22/3315298/29489/en/AIM-ImmunoTech-to-Present-in-the-Webull-Corporate-Connect-Webinar-Series.html · 6/22/2026+0.40
https://seekingalpha.com/article/4912000-aim-immunotech-inc-aim-discusses-ampligens-potential-role-in-addressing-bundibugyo-ebola · 6/4/2026+0.60
https://www.globenewswire.com/news-release/2026/05/27/3301981/29489/en/AIM-ImmunoTech-Announces-Emerging-Ebola-Opportunity-for-Ampligen-Amid-Escalating-Global-Health-Concerns-and-WHO-Emergency-Declaration.html · 5/27/2026+0.80
https://www.marketbeat.com/instant-alerts/aimia-q1-earnings-call-highlights-2026-05-16/ · 5/16/2026+0.40
https://www.globenewswire.com/news-release/2026/04/13/3272939/29489/en/AIM-ImmunoTech-Provides-Routine-Update-on-Annual-Filings.html · 4/13/2026-0.40
https://www.benzinga.com/trading-ideas/movers/26/03/51381605/whats-going-on-with-aim-immunotech-stock-friday · 3/20/2026+0.60
https://www.globenewswire.com/news-release/2025/12/01/3197061/29489/en/AIM-ImmunoTech-to-Participate-in-Live-Fireside-Chat-on-Virtual-Investor-Closing-Bell-Series.html · 12/1/2025+0.40
https://www.globenewswire.com/news-release/2025/11/18/3190059/29489/en/AIM-ImmunoTech-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress-Across-Pipeline-with-Strategic-Focus-on-Pancreatic-Cancer-Clinical-Program.html · 11/18/2025+0.60
https://www.globenewswire.com/news-release/2025/11/10/3184613/29489/en/AIM-ImmunoTech-Details-New-UPMC-Abstract-on-Completed-Clinical-Trial-Involving-Ampligen-s-Synergistic-Potential-in-the-Treatment-of-Advanced-Recurrent-Ovarian-Cancer.html · 11/10/2025+0.80
https://www.globenewswire.com/news-release/2025/09/25/3156304/29489/en/AIM-ImmunoTech-Secures-Patent-in-Japan-Through-2039-for-Novel-Cancer-Therapy-Combining-Ampligen-Rintatolimod-with-Checkpoint-Inhibitors.html · 9/25/2025+1.00
https://www.globenewswire.com/news-release/2025/08/15/3134244/29489/en/AIM-ImmunoTech-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html · 8/15/2025+0.80
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
